Clinical trials: Primary
Melanoma, Non Small Cell Lung Cancer
Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors
AI-061 is a co-formulation drug product (DP) consisting of 1:1 ratio mix of AI-025, an anti-PD-1 antibody, and ONC-392, an anti-CTLA-4 antibody.
- Conditions
- Melanoma, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, High Grade Serous Adenocarcinoma of Ovary
- Trial name
- PRESERVE-009 (NCT05858736)
- Testing
- AI-061
- Where
- 5 sites in Australia
- Volunteers
- 18 people
- Sponsor
- OncoC4, Inc.
Platinum-resistant Ovarian Cancer
Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer
This phase 3 study will be conducted in different countries all over the world. The purpose of this study is to compare how well Rina-S works against platinum-resistant ovarian cancer compared to chemotherapy drugs that are…
- Trial name
- RAINFOL-02 (NCT06619236)
- Testing
- Rina-S, Paclitaxel, Topotecan
- Where
- 177 sites in United States, Australia and 16 more
- Volunteers
- 584 people
- Sponsor
- Genmab
Hematopoietic Neoplasm
Phase II, Open Label, Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With Ruxolitinib
Primary Objective: To evaluate the efficacy of once daily dose of SAR302503 in subjects previously treated with ruxolitinib and with a current diagnosis of intermediate-1 with symptoms, Intermediate-2 or high-risk primary…
- Trial name
- JAKARTA2 (NCT01523171)
- Testing
- SAR302503
- Where
- 42 sites in United States, Austria and 8 more
- Volunteers
- 97 people
- Sponsor
- Bristol-Myers Squibb
Vaccines, Combined, Hexavalent Vaccine
Safety, Tolerability, and Immunogenicity of Vaxelis™ in Children Previously Vaccinated With Vaxelis™ or Hexyon™ (V419-016)
The primary objectives of this study are to evaluate the safety, tolerability, and immunogenicity of a booster dose of Vaxelis™ (V419) given at ~11 to 13 months of age in healthy participants who were previously vaccinated with a…
- Trial name
- NCT05289271
- Testing
- Vaxelis™
- Where
- 13 sites in Germany, Italy and 1 more
- Volunteers
- 168 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Primary Sjögren Syndrome
A Study to Evaluate the Efficacy and Safety of Iguratimod Compared to Placebo in Patients With Active Primary Sjogren's Syndrome.
The purpose of this study is to evaluate the efficacy and safety of iguratimod compared to placebo in patients with active primary Sjogren's Syndrome.
- Trial name
- NCT04830644
- Testing
- Iguratimod
- Where
- 30 sites in China
- Volunteers
- 144 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Osteoarthritis, Total Knee Arthroplasty
Use of Cold and Compression Therapy With Total Knee Replacement Patients
The purpose of the study is to evaluate the effectiveness of a device that delivers cold and intermittent compression as compared to ice and compressive wraps on patients who have undergone knee replacement.
- Trial name
- NCT00712816
- Testing
- Game Ready Injury Treatment System (CoolSystems Inc.), Ice with compressive bandages
- Where
- 11 sites in United States, Australia
- Volunteers
- 224 people
- Sponsor
- CoolSystems, Inc.
Migraine
Study to Test a Marketed Product in the Treatment of Migraine-associated Nausea
Study to test the effectiveness of a marketed drug in the treatment of migraine-associated nausea.
- Trial name
- NCT00250458
- Testing
- Comparator: Rizatriptan
- Volunteers
- 346 people
- Sponsor
- Organon and Co
Hepatitis A, Hepatitis B
Long-term Persistence Study in Healthy Adults Previously Vaccinated With Twinrix Adult
This study will evaluate the persistence of the immune response to HAV (hepatitis A virus) antigens and HBs (hepatitis B surface) antigens in healthy adults previously vaccinated with Twinrix Adult in the primary study, HAB-032…
- Trial name
- NCT01037114
- Testing
- Blood sampling, Engerix-B, Havrix
- Where
- Belgium
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Neisseria Meningitidis, Haemophilus Influenzae Type b
Primary & Booster Study in Infants to Demonstrate Non-inferiority, Persistence & Immunogenicity of Hib-MenC Vaccine
The purpose of this primary vaccination phase is to demonstrate the non-inferiority of two doses of Biologicals' Hib-MenC conjugate vaccine when given with Infanrix™ penta to infants (at 3 \& 5m) compared to NeisVac-C™ given with…
- Trial name
- NCT00327184
- Testing
- Haemophilus influenzae type b- and meningococcal serogroup C (vaccine), Infanrix Penta, Infanrix hexa
- Where
- 16 sites in Finland, Italy
- Volunteers
- 709 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Total Hip Arthroplasty
Bone Remodeling Around a Trabecular Titanium Cup in Total Hip Arthroplasty
The goal of this randomized controlled trial is to measure the periprosthetic bone mineral density changes around a 3D-printed highly-porous titanium acetabular cup used in primary total hip arthroplasty compared to a standard…
- Trial name
- NCT06287021
- Testing
- Jump System Traser® cup, Jump System HAX-Pore® cup
- Where
- 2 sites in Italy
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Permedica spa
Multiple Sclerosis
Correlation Between Multiple Sclerosis Functional Composite (MSFC) and Expanded Disability Status Scale (EDSS) in Patients With Multiple Sclerosis (MS) in Argentina
This observational study is being conducted to evaluate the usefulness of the MSFC and its relationship with EDSS scores in subjects with MS in Argentina.
- Trial name
- NCT01080014
- Where
- Argentina
- Volunteers
- 252 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Multiple Sclerosis
Real World Effectiveness, Persistence, Tolerability, and Safety of Ofatumumab in Clinical Practice
This was a retrospective cohort study using the electronic medical record (EMR) database from Cleveland Clinic. The data was analyzed at start of ofatumumab (OMB) therapy (baseline, defined as 6 months prior to OMB initiation)…
- Trial name
- NCT06737419
- Where
- United States
- Volunteers
- 175 people
- Sponsor
- Novartis Pharmaceuticals
Prostatic Hyperplasia
Study to Evaluate the Effect of ALNA® (Tamsulosin) on the Primary Symptoms of Benign Prostatic Hyperplasia
The aims of this observational study are to identify the primary BPH symptoms responsible for the patients to consult a urologic practice, resulting in the prescription of ALNA®, to assess the clincial efficacy on an improved…
- Trial name
- NCT02244268
- Testing
- ALNA®
- Volunteers
- 3,629 people
- Sponsor
- Boehringer Ingelheim
Postmenopausal Women With Primary Osteoporosis
STEP: Study of Imaging Techniques (ImaTx and DXA) in Postmenopausal Women With OstEoporosis Using Preotact (FP-008-ES)
The primary objective of the study is to explore the relationship between a new image technology (ImaTx), that analyzes the trabecular structure of the bone using digitized radiographs and the bone mineral density (BMD) measured…
- Trial name
- NCT00583518
- Testing
- Parathyroid hormone (PTH)
- Where
- Denmark
- Volunteers
- 129 people
- Sponsor
- Nycomed
Hepatitis A, Hepatitis B
Antibody Persistence & Immune Memory in Healthy Adults Previously Vaccinated With Twinrix Adult
This study will evaluate the persistence of the immune response to HAV (Hepatitis A Virus) antigens and HBs (Hepatitis B surface) antigens in healthy adults previously vaccinated with GlaxoSmithKline (GSK) Biologicals' Twinrix…
- Trial name
- NCT01000324
- Testing
- Blood sampling, Engerix-B, Havrix
- Where
- Belgium
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hereditary Angioedema (HAE)
Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema
The purpose of this study is to assess the efficacy and safety of subcutaneous administration of a liquid formulation of C1 esterase inhibitor for the prevention of angioedema attacks in adolescent and adult subjects with…
- Trial name
- NCT02584959
- Testing
- C1 esterase inhibitor [human] liquid
- Where
- 27 sites in United States, Canada and 5 more
- Volunteers
- 75 people
- Sponsor
- Shire
Adenocarcinoma
Gemcitabine and Pemetrexed in Primary Unknown Adenocarcinoma
There is no standard treatment for the patient population being asked to participate in this study. Although one current regimen, used by some investigators, has a high rate of response compared to other therapies, it is…
- Trial name
- NCT00191503
- Testing
- Pemetrexed, Gemcitabine
- Where
- 2 sites in Canada
- Volunteers
- 30 people
- Sponsor
- Eli Lilly and Company
Myelofibrosis
PK of Pacritinib in Patients With Mild, Moderate, Severe Renal Impairment and ESRD Compared to Healthy Subjects
This is a Phase 1 open label, single dose, 5 parallel-group study in which a single 400 mg dose of pacritinib will be administered orally to patients with renal impairment (mild, moderate, severe, and patients with ESRD requiring…
- Trial name
- NCT02807077
- Testing
- Pacritinib
- Where
- 3 sites in Germany, Moldova and 1 more
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- CTI BioPharma
Diabetes Mellitus, Type 1
Insulin Glargine in Type I Diabetes Mellitus> Main Study "AT.LANTUS": A Trial Comparing Lantus Algorithms to Achieve Normal Blood Glucose Targets in Subjects With Uncontrolled Blood Sugar. Sub-study: "HALT"(Hypoglycaemia Avoidance With Lantus Trial)
Primary objective: AT.LANTUS main study* To determine the optimal treatment algorithm for insulin glargine based on the incidence of severe hypoglycaemia.(*Target Number of patients for the main study:2346) HALT Sub-study** To…
- Trial name
- AT-LANTUS (NCT00390728)
- Testing
- Insulin Glargine
- Volunteers
- 2,346 people
- Sponsor
- Sanofi
Kidney Diseases, Kidney Diseases, Chronic
Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
The purpose of this study is to determine if zigakibart is safe and effective for long-term use in patients with immunoglobulin A nephropathy (IgAN).
- Conditions
- Kidney Diseases, Kidney Diseases, Chronic, Urological Diseases, Glomerulonephritis
- Trial name
- NCT06858319
- Testing
- zigakibart
- Where
- 26 sites in United States, Argentina and 7 more
- Volunteers
- 220 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.